Our firm is about people. That is our motto and that will always be our reality.
We do our best to get to know our clients, understand their situations, and get them the compensation they deserve.
At TorHoerman Law, we believe that if we continue to focus on the people that we represent, and continue to be true to the people that we are – justice will always be served.
Without our team, we would’nt be able to provide our clients with anything close to the level of service they receive when they work with us.
The TorHoerman Law Team commits to the sincere belief that those injured by the misconduct of others, especially large corporate profit mongers, deserve justice for their injuries.
Our team is what has made TorHoerman Law a very special place since 2009.
Bard PowerPort catheter infection lawsuit claims center on allegations that defects in Bard’s implantable port systems increased the risk of bacterial contamination and bloodstream infection.
Catheter-related infections can lead to serious medical consequences, including sepsis, organ damage, prolonged hospitalization, and other life-threatening complications that disrupt a patient’s overall health.
TorHoerman Law is currently accepting new claims from individuals who developed infections after receiving a Bard PowerPort device.
The Bard PowerPort device is commonly used to provide long-term venous access for infusion therapy, including treatment for cancer patients undergoing chemotherapy.
Bard PowerPort lawsuits allege that defects in the catheter or port system increased the risk of infection, device failure, and other related complications.
Plaintiffs also allege that fracture, migration, thrombosis, or material breakdown created conditions that allowed bacteria to spread or made treatment more difficult.
Reported infections in these cases range from local port-site infections to bloodstream infections and other serious complications requiring hospitalization or device removal.
Some patients allege that infection developed after the catheter failed inside the body or stopped functioning as intended.
Federal lawsuits involving Bard implanted port catheter products are pending in MDL No. 3081 in the District of Arizona.
TorHoerman Law is reviewing Bard PowerPort claims involving catheter infection, device failure, and other complications linked to implanted port catheter products.
If you or a loved one were injured by a Bard PowerPort Device, you may be eligible to file a Bard PowerPort Lawsuit and seek compensation.
Contact TorHoerman Law for a free consultation.
You can also use the chatbot on this page to find out if you qualify for the Bard PowerPort lawsuit instantly.
The Bard PowerPort, manufactured by Bard Access Systems Inc., is a medical device designed to provide access to a patient’s bloodstream.
This access point is critical in modern medicine, allowing healthcare professionals to perform various medical procedures.
The Bard PowerPort consists of a small chamber and catheter surgically implanted beneath the patient’s skin.

The catheter is then threaded into a large vein, typically in the chest, as a conduit for administering drugs, fluids, or blood products.
This device is widely used in cancer treatment, long-term antibiotic therapy, and other medical conditions that require frequent intravenous access.
Bard PowerPort devices are primarily used by patients who require long-term intravenous therapy or frequent access to their veins.

Patients who use the Bard PowerPort device may include:
The convenience and supposed reliability of the Bard PowerPort device have made it an attractive option for healthcare providers and patients seeking a more comfortable and efficient means of delivering crucial treatments.
As we’ve established, the Bard PowerPort is a type of subcutaneous central venous port designed to provide reliable long-term vascular access, particularly for patients undergoing chemotherapy and other infusion therapies.
While these devices are routinely placed and managed through interventional radiology or surgical procedures, a growing number of patients have reported serious complications after having a Bard implant port system implanted.
The Bard port catheter lawsuit claims that defects in the device’s design and catheter material increased the likelihood of mechanical failure and patient injury.
The Bard PowerPort is made of a silicone injection port and a polyurethane/ChronoFlex catheter.
Over time, this catheter material may degrade or develop surface changes with repeated use and long-term implantation.
These changes can affect the condition of the catheter and may allow bacteria to attach to the surface or enter the bloodstream during use.
Medical literature recognizes that implanted ports already carry independent risk factors for complications due to repeated access, immune suppression, and prolonged use, which are typically managed by medical providers during treatment.
However, plaintiffs allege that defective PowerPort devices posed risks beyond those normally expected, leading to premature failure, internal damage, and the need for emergency intervention.
Legal actions often involve severe infections, including sepsis, septic shock, and endocarditis, as a result of Bard PowerPort usage.
Reported adverse events include both mechanical and vascular injuries caused by the Bard PowerPort implantable port device, some of which required device removal or additional surgeries.

Patients involved in the litigation have reported a wide range of major complications, including:
While infection-related injuries are a central focus of many claims, they represent only one category of harm associated with the PowerPort system.
The litigation highlights how structural failure, material degradation, and loss of catheter integrity can expose patients to serious outcomes seen across common power port complications, risks, and symptoms.
Subsequent sections examine infection-related complications in greater detail and explain how they factor into individual Bard PowerPort claims.
In many Bard PowerPort cases, infection is a central injury, often developing after the device has been in place for an extended period.
Implantable ports like the Bard port-a-cath are designed to allow repeated access for chemotherapy, medications, and blood draws, but they rely on the long-term integrity of the catheter and port housing to remain safe.
Plaintiffs allege that when catheter material degrades over time, microscopic cracks and surface irregularities can form, creating an environment where bacteria can adhere and proliferate.
According to allegations in the litigation, catheter failure may allow bacteria to enter the bloodstream directly, transforming what might begin as a localized port infection into a systemic condition.
Infection is a common complication of implanted venous access devices, but Bard PowerPort claims argue that the rate and severity of infections exceeded what patients and providers were warned to expect.
In some cases, infections progressed rapidly despite antibiotic treatment, leaving surgical intervention, including urgent port removal, the only viable option.
Once infection spreads beyond the port site, patients may experience serious medical complications requiring prolonged hospitalization, intensive care, or multiple invasive procedures.
These infections can disrupt cancer treatment schedules, delay infusions, and place already vulnerable patients at heightened risk.
The litigation further alleges that defective catheter design contributed to a cascade of associated complications, particularly when bacterial contamination reached central circulation.

Possible complications of catheter infections include:
Catheter infections associated with Bard PowerPort devices are believed to result from a combination of design-related issues and the inherent risks of implanted vascular access systems.
Like many implantable devices, a port catheter device must remain stable and intact inside the body over long periods while being accessed repeatedly for medications, chemotherapy, and long-term IV treatments.
When any component of the device degrades or becomes compromised, it can create pathways for bacteria to enter the body and reach the bloodstream.
In addition to infection risk, changes in catheter position may also lead to migration symptoms such as pain, swelling, or discomfort as the device shifts or loses stability over time.
Plaintiffs allege that Bard PowerPort catheters are manufactured using Chronoflex AL, a blend of polyurethane and barium sulfate intended to provide flexibility and imaging visibility.
Over time, this material may weaken and develop cracks, fissures, or surface irregularities, particularly at stress points along the catheter.
These microscopic defects can promote bacterial growth, allowing pathogens to colonize areas that are difficult for the immune system or antibiotics to reach.
Even when the device is inserted with proper placement and sterile technique at the surgical site, degraded catheter surfaces may still pose problems with Bard Power Port devices.
As bacteria accumulate within damaged sections of the catheter, localized port infections can progress into more serious bloodstream infections.
This risk is heightened in patients who rely on frequent access to the port for ongoing treatment, as repeated use increases mechanical stress and exposure.
The Bard PowerPort MDL argues that these material-related vulnerabilities contributed to infection rates and severity beyond what patients and providers were warned to expect.

The materials used in the construction of Bard PowerPort devices, while chosen for their biocompatibility, strength, and durability, are not impervious to the rigors of long-term use within the human body.
Over time, these materials may undergo wear, tear, and degradation.
Such structural compromises render them more susceptible to developing cracks or fissures, which, unfortunately, can serve as breeding grounds for bacteria.
While not immediately apparent, this material vulnerability poses a significant risk to patients who rely on Bard PowerPort devices for continuous medical care.
These microscopic openings provide opportunistic pathogens with a route to access blood vessels, thereby increasing the likelihood of infection.
The presence of a catheter within the body, although medically necessary, represents an inherent foreign body.
In essence, it creates an artificial passage into the bloodstream.
This entry point can be exploited by bacteria and other microorganisms.
While typically sterile upon insertion, this foreign body is not immune to contamination, especially in the presence of the aforementioned material vulnerabilities.
When the catheter’s integrity is compromised through fracturing or cracking, it becomes a beacon for bacteria, allowing them to enter and colonize the area.
This can set the stage for infection, blood clots, and deep vein thrombosis, potentially leading to grave consequences if not promptly addressed.
Many patients requiring Bard PowerPort devices do so for extended periods, sometimes several months or even years.
While these devices offer the advantage of consistent intravenous access, this extended duration of placement also increases the susceptibility to infections over time.
The longer a Bard PowerPort device remains in place, the greater the opportunity for contaminants to infiltrate the system, potentially leading to serious injuries and conditions.
Lawsuits allege design defects in the Bard PowerPort catheters that can lead to severe infections, sepsis, and blood clots.
Bard PowerPort lawsuits claim that infection-related injuries developed during ongoing use of the device.
Catheter infections, while often underestimated, can have far-reaching and profound consequences for patients, affecting their physical health and overall well-being.
In claims involving an implantable port catheter device, the issue is often how an infection progresses beyond the port site and affects surrounding systems.
Severe infection-related claims involve conditions such as sepsis, septic shock, and endocarditis, as reported in Bard PowerPort usage.
These health complications are being reviewed within the Bard PowerPort multidistrict litigation.

Among the most critical complications stemming from catheter infections are systemic infections, which pose a grave risk to patients.
These infections, originating from catheter-related complications, can rapidly spread throughout the body.
Sepsis, a life-threatening condition, represents the ultimate consequence of unchecked systemic infections.
It is characterized by widespread inflammation, organ dysfunction, and a heightened risk of mortality.
When infections infiltrate the bloodstream via catheter-related issues, they can provoke an uncontrolled immune response, sending the body into a state of crisis.
Organs may begin to fail, leading to a dire medical emergency. Sepsis requires immediate and aggressive medical intervention, often involving intensive care and treatment with antibiotics and other medications.
Infections localized at the catheter insertion site can inflict significant discomfort and distress upon patients.
This localized inflammation can manifest as pain, swelling, redness, and irritation, impairing the patient’s quality of life.
Pain can be incredibly disruptive, interfering with daily activities and hindering the effectiveness of ongoing treatment.
Additionally, the physical discomfort can take a toll on a patient’s emotional well-being, further complicating the healing process.
Catheter infections not only jeopardize the patient’s health but also compromise the very functionality of the Bard PowerPort device itself.
When an infection takes hold, it can impede the device’s operation, hindering the delivery of critical medications, fluids, or other essential treatments.
In some cases, the device may become entirely inoperative, necessitating its removal or replacement.
Some lawsuits also cite thrombosis (blood clots), catheter fractures, or device migration as complications requiring surgical interventions.
Thrombosis, the formation of blood clots within the blood vessels, is another serious complication associated with the Bard PowerPort.
The most common complication associated with the Bard PowerPort is a fracture of the device itself. Fractured catheters may lead to the device eroding through the skin, infections, and blood clots, which can be fatal.
This translates to increased physical and emotional strain on the patient and potential delays in receiving necessary treatments.
Severe infections stemming from Bard PowerPort catheters often mandate extended hospital stays and intensive treatment.
These prolonged hospitalizations impose a multifaceted burden on patients and their families.
In addition to the physical toll, they can be emotionally taxing, leading to anxiety and distress.
Moreover, the financial implications of extended hospitalization can be overwhelming, further exacerbating the challenges faced by patients and their loved ones.
Bard PowerPort cases are part of a broader implantable port catheter lawsuit involving allegations that Bard devices caused serious injuries after implantation.
The litigation is centralized in the United States District Court for the District of Arizona, where Judge David Campbell oversees coordinated pretrial proceedings.
The United States Judicial Panel on Multidistrict Litigation, often called the judicial panel, created the MDL to manage similar cases filed in courts across the country.
Plaintiffs have brought claims against Bard and Becton Dickinson and Company, Bard’s parent company, alleging that the Bard Power Port device was defectively designed or manufactured and caused complications such as fracture, thrombosis, infection, and migration.
The court has held repeated case-management proceedings, including a case management conference schedule and later conference orders as the MDL expanded.
The record also shows that the Bard PowerPort MDL grew steadily as more pending lawsuits were filed and transferred into the Arizona district court.
Recent orders entered by Judge Campbell reflect ongoing preparation for trial-focused proceedings, including work tied to bellwether selection and pretrial scheduling.

Common Bard PowerPort lawsuit allegations include:
The court is also moving toward trial testing through selected bellwether cases, with bellwether trials scheduled for 2026.
Orders from Judge David G. Campbell show that pretrial work has included the discovery process, expert challenges, and trial scheduling tied to those early cases.
A status conference schedule has remained part of the court’s management of the MDL as it organizes motion practice and discovery deadlines.
The outcome of those early proceedings may shape how similar Bard PowerPort claims are evaluated going forward.
There is no established “average” settlement for Bard Port Catheter lawsuit settlement claims because the Bard PowerPort litigation is ongoing and no global settlement has been announced.
Bellwether trials in the Bard PowerPort litigation are scheduled to begin in April 2026, which will help assess the strength of the claims and influence future settlement negotiations.
TorHoerman Law’s Bard PowerPort attorneys estimate that potential powerport lawsuit settlement amounts could range from $10,000 to over $250,000, depending on the direction of the litigation and the facts of an individual case.
The potential settlement value of individual Bard PowerPort claims will depend on several case-specific factors, particularly the type of device-related event alleged, the severity of the resulting injury, and the extent of documented treatment.

For example:
Projected value may increase when medical records show catheter fracture or migration, serious infection, invasive removal or revision procedures, extended hospitalization, lasting impairment, or significant disruption to treatment.
Claims with earlier detection, limited complications, and less extensive follow-up care may fall closer to the lower end of projected ranges.
Claims involving more severe injuries, prolonged treatment, documented complications, and substantial medical bills may fall substantially higher.
Eligibility in a Bard PowerPort lawsuit depends on whether the available medical and factual record supports a product liability claim involving the implanted device.
Most claims involve individuals who had a Bard PowerPort implanted and later developed a diagnosed complication such as thrombosis, infection, fracture, or device migration.
A qualifying case typically requires documentation showing the device was used as intended and that the injury developed after implantation.
Medical records are used to evaluate when symptoms began, how the condition progressed, and what treatment was required.

Imaging studies, physician notes, and procedural records may help determine whether the catheter’s condition or position contributed to the complication.
Timing is also important, as courts often examine how closely the injury followed device use and whether other causes may be present.
Many claims involve patients who relied on the device for extended treatment, including chemotherapy or other long-term infusion therapy.
A case review can help determine whether the evidence supports a connection between the Bard PowerPort device and the reported injury.
Evidence plays a central role in determining whether a Bard PowerPort claim can be supported in a product liability case.
Medical records are used to establish when the device was implanted, when symptoms developed, and how the condition progressed over time.
Early documentation is especially important, including when a patient sought care or reported symptoms to a doctor immediately after complications began.
Consistent, well-documented records help connect the device to the injury and clarify the course of treatment that followed.

Evidence in these cases may include:
The Bard PowerPort lawsuit highlights the challenges faced by patients who have experienced catheter infections due to using this medical device.
While port catheters have been a valuable tool in medical treatment, the susceptibility to infections due to material vulnerabilities in Bard PowerPort devices has raised serious concerns.
Patients affected by these infections are seeking justice through lawsuits to hold the manufacturer accountable for the harm they have endured.

If you or a loved one has been injured by a Bard PowerPort device, you may be eligible to file a Bard PowerPort Lawsuit.
Contact TorHoerman Law for a free consultation.
You can use the chatbot on this page to determine if you qualify for the Bard PowerPort Lawsuit instantly.
A Bard PowerPort injury lawyer can provide guidance and support during this difficult time, in the pursuit of fair compensation and accountability.
Reach out to our team with any questions you may have about the Bard PowerPort Lawsuit.
Yes, there have been FDA recalls involving certain Bard PowerPort products, but it is important to understand what those recalls did and did not cover.
The FDA issued Class II recalls for specific PowerPort components and models after identifying manufacturing or design issues that could pose health risks. One recall, initiated in October 2019, involved a tunneler component used with PowerPort implantable ports due to a mismatch that could affect device performance.
Another recall, initiated in January 2020, involved the PowerPort ClearVUE Slim Implantable Port, related to a catheter lock mechanism that did not meet specifications.
These recalls did not explicitly address all of the catheter material degradation and fracture issues alleged in current lawsuits.
Many plaintiffs in the Bard PowerPort litigation report injuries that occurred outside the scope or time frame of the recalls, including infections, fractures, and migration of catheter components.
The lawsuits argue that Bard continued to market the device despite knowing about broader risks that were not fully disclosed through recall notices.
As a result, the existence of limited recalls has become part of the larger factual background in the Bard PowerPort litigation, but it does not resolve or negate the claims being pursued in court.
Medical documentation plays a central role in evaluating Bard PowerPort catheter infection claims because it shows how the device was implanted, how the infection developed, and how it was treated.
Records help establish timelines, rule out alternative causes, and document the severity of the infection and related complications.
Important records often include:
These records help attorneys and medical experts evaluate whether the infection may be linked to device-related issues and how it fits within the broader Bard PowerPort litigation.
Underlying health conditions may be reviewed when evaluating Bard PowerPort claims, but they do not automatically prevent someone from pursuing a lawsuit.
In many cases, patients receiving implantable port devices already face complex medical challenges, including cancer, immune suppression, or conditions such as diabetes mellitus, which can increase baseline risks.
The central question in Bard PowerPort litigation is whether defects in the device or inadequate warnings contributed to injuries beyond those inherent medical risks.
Even when a patient has preexisting conditions, lawsuits may proceed if evidence suggests the device failed or performed in a way that exposed the patient to additional harm.
No global PowerPort lawsuit settlement has been reached as of March 2026, but potential individual payouts could range from $10,000 to nearly $1,000,000. These projections are based on ongoing Bard PowerPort multidistrict litigation and early case evaluations.
As bard powerport lawsuit updates continue, outcomes from bellwether trials and pretrial proceedings may influence how future claims are resolved.
Each case is assessed individually based on documented injuries, device performance, and supporting evidence. Settlement discussions remain tied to how courts evaluate infection-related and device-related complications across similar claims.
Settlement amounts in Bard PowerPort cases depend on what actually happened to the patient and how serious the complications were.
The average settlement payout for the PowerPort lawsuits is projected to be between $150,000 to $300,000, with some claims exceeding $1 million.
Factors that can affect individual settlement values include injury severity, whether the device was removed, length of medical treatment, lost wages, and pain and suffering.
Cases involving infection or device failure related to an implanted port catheter device are usually reviewed based on medical records and what is shown during the discovery process.
The Bard PowerPort litigation is progressing in federal court through a series of bard powerport bellwether trials, which are used to test evidence and legal arguments before representative cases go before a jury.
The first bellwether trial is scheduled as part of this process, and each bard powerport trial will provide insight into how juries evaluate claims involving alleged device defects and related injuries.
These early trial outcomes often influence how both sides approach resolution, including discussions surrounding a potential powerport settlement.
At this stage, no global settlement has been reached, and any references to PowerPort lawsuit settlement amounts are estimates rather than confirmed outcomes.
Owner & Attorney - TorHoerman Law
Here, at TorHoerman Law, we’re committed to helping victims get the justice they deserve.
Since 2009, we have successfully collected over $4 Billion in verdicts and settlements on behalf of injured individuals.
Would you like our help?
At TorHoerman Law, we believe that if we continue to focus on the people that we represent, and continue to be true to the people that we are – justice will always be served.
Do you believe you’re entitled to compensation?
Use our Instant Case Evaluator to find out in as little as 60 seconds!
In this case, we obtained a verdict of $495 Million for our client’s child who was diagnosed with Necrotizing Enterocolitis after consuming baby formula manufactured by Abbott Laboratories.
In this case, we were able to successfully recover $20 Million for our client after they suffered a Toxic Tort Injury due to chemical exposure.
In this case, we were able to successfully recover $103.8 Million for our client after they suffered a COX-2 Inhibitors Injury.
In this case, we were able to successfully recover $4 Million for our client after they suffered a Traumatic Brain Injury while at daycare.
In this case, we were able to successfully recover $2.8 Million for our client after they suffered an injury due to a Defective Heart Device.
Here, at TorHoerman Law, we’re committed to helping victims get the justice they deserve.
Since 2009, we have successfully collected over $4 Billion in verdicts and settlements on behalf of injured individuals.
Would you like our help?